Steeve Provencher
Elite in Hypertension

Steeve Provencher

Quebec, QC, CA 
Elite in Hypertension
Quebec, QC, CA 
OverviewLocationsClinical Research

Overview

Steeve Provencher practices in Quebec, Canada. Mr. Provencher is rated as an Elite expert by MediFind in the treatment of Hypertension. His top areas of expertise are Pulmonary Hypertension, Hypertension, Cerebral Hypoxia, Liver Embolization, and Endoscopy.

His clinical research consists of co-authoring 177 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 113 articles and participated in 8 clinical trials in the study of Hypertension.

Gender
Male

Locations

Quebec, QC, Canada
Other Locations
Canada
Laval, QC, Canada
Toronto, ON, Canada
Edmonton, AB, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Active_not_recruiting
Publish Date: June 24, 2025
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 3
Olaparib for Pulmonary Arterial Hypertension: a Multicenter Clinical Trial
Olaparib for Pulmonary Arterial Hypertension: a Multicenter Clinical Trial
Enrollment Status: Terminated
Publish Date: February 12, 2025
Intervention Type: Drug
Study Drug: Olaparib
Study Phase: Phase 1/Phase 2
Study of Angiogenic Cell Therapy for Progressive Pulmonary Hypertension: Intervention With Repeat Dosing of eNOS-enhanced EPCs
Study of Angiogenic Cell Therapy for Progressive Pulmonary Hypertension: Intervention With Repeat Dosing of eNOS-enhanced EPCs
Enrollment Status: Terminated
Publish Date: January 31, 2025
Intervention Type: Biological
Study Drug: Autologous EPCs transfected with human eNOS
Study Phase: Phase 2/Phase 3
Skeletal Muscle Mitochondrial Abnormalities and the Metabolic Syndrome in Pulmonary Arterial Hypertension
Skeletal Muscle Mitochondrial Abnormalities and the Metabolic Syndrome in Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: April 18, 2023
Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study
Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study
Enrollment Status: Completed
Publish Date: April 25, 2022
Intervention Type: Drug
Study Drug: Apabetalone
Study Phase: Early Phase 1
Olaparib for Pulmonary Arterial Hypertension: a Pilot Clinical Study
Olaparib for Pulmonary Arterial Hypertension: a Pilot Clinical Study
Enrollment Status: Terminated
Publish Date: August 26, 2020
Intervention Type: Drug
Study Phase: Early Phase 1
View 7 Less Clinical Trials

177 Total Publications

Impaired Lung BCAA Metabolism Promotes Ferroptosis and Resultant Pulmonary Arterial Hypertension-Associated Hepatopathy.
Impaired Lung BCAA Metabolism Promotes Ferroptosis and Resultant Pulmonary Arterial Hypertension-Associated Hepatopathy.
Journal: bioRxiv : the preprint server for biology
Published: September 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Provencher's expertise for a condition
ConditionClose
    View All 20 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile